Overview

HFHS-1801-A Pilot Study of Immunotherapy as Consolidation Therapy for Patients With Recurrent Head and Neck Cancer

Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
The study is a pilot study to explore the feasibility and efficacy of immunotherapy following salvage surgery for recurrent head and neck cancer.
Phase:
Early Phase 1
Details
Lead Sponsor:
Henry Ford Health System
Treatments:
Pembrolizumab